Approaches to the therapy of non-alcoholic fatty liver disease.
Tikhomirova A.S., Baikova I.E., Gogova L.M., Kislyakov V.A., Volynkina V.M., Alieva A.M., Nikitin I.G.

Russian National Research Medical University named after N.I. Pirogov, Moscow

Non-alcoholic fatty liver disease (NAFLD) is currently the most common liver disease affecting approximately one-third of the world's population. NAFLD has become a serious problem because of its prevalence, difficulties in diagnosis, complex pathogenesis, and the lack of optimal, developed and approved treatment methods. At present, for the treatment of this disease in the stage of simple steatosis, the methods for correcting a lifestyle with the goal of reducing weight are commonly used. Changing the lifestyle is the first step in the treatment of NAFLD. Reducing the weight by at least 5% reduces the severity of steatosis of the liver, and weight loss by 7-10% contributes to the regress of inflammation in the liver. Potentially effective pharmaceutical agents are: weight loss drugs, hypoglycemic agents (thiazolidinediones, metformin, incretin mimetics), lipid-lowering drugs (statins, omega-3 fatty acids), antioxidants, hepatoprotectors (ursodeoxycholic acid, essential phospholipids). The new strategies and drugs developed today potentially have greater efficacy compared to the registered drugs. Cirrhosis of the liver in the outcome of NAFLD - is one of the top three causes of liver transplantation (along with HCV infection and alcohol). Patients with NAFLD who undergo transplantation have a high risk of fatal outcomes from cardiovascular complications and sepsis, and low risks of graft failure.

Key words: non-alcoholic fatty liver disease, essential phospholipids, obesity.
For citation: Tikhomirova A.S., Baikova I.E., Gogova L.M. et al. Approaches to the therapy of non-alcoholic fatty liver disease. // RMJ. 2017. № 10. P. 738 –744.